Sign up to save your podcasts
Or
Share The Emerging Role of HER2 (ERBB2) Mutations in NSCLC
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
The Emerging Role of HER2 (ERBB2) Mutations in NSCLC
CME credits: 0.25
Valid until: 19-04-2023
Claim your CME credit at https://reachmd.com/programs/cme/the-emerging-role-of-her2-erbb2-mutations-in-nsclc/13695/
Since the release of this activity, the FDA has approved the use of trastuzumab deruxtecan-nxki for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating human epidermal growth factor receptor 2 HER2 (ERBB2) mutations, as determined by an FDA-approved test, for those who have received prior systemic therapy. Visit the FDA statement dated August 11, 2022 to learn more.
HER2-targeted therapies have demonstrated substantial survival benefits for patients with HER2-positive breast cancer. So can we use those agents for HER2-positive NSCLC? Join Dr. Lyudmila Bazhenova and Dr. Benjamin Levy as they discuss the latest data around emerging agents for HER2-positive NSCLC and the best way to identify these mutations in clinical practice.
=
View all episodes
By ReachMD
4.3
33 ratings
CME credits: 0.25
Valid until: 19-04-2023
Claim your CME credit at https://reachmd.com/programs/cme/the-emerging-role-of-her2-erbb2-mutations-in-nsclc/13695/
Since the release of this activity, the FDA has approved the use of trastuzumab deruxtecan-nxki for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating human epidermal growth factor receptor 2 HER2 (ERBB2) mutations, as determined by an FDA-approved test, for those who have received prior systemic therapy. Visit the FDA statement dated August 11, 2022 to learn more.
HER2-targeted therapies have demonstrated substantial survival benefits for patients with HER2-positive breast cancer. So can we use those agents for HER2-positive NSCLC? Join Dr. Lyudmila Bazhenova and Dr. Benjamin Levy as they discuss the latest data around emerging agents for HER2-positive NSCLC and the best way to identify these mutations in clinical practice.
=